Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]
Discontinued
Reference number: GID-TA11318
Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together have been revised. It is anticipated that the appraisal will begin in early-October 2023 when we will write to you about how you can get involved